Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

A basic fact I learned from the arbitration claim

Message Board Public Reply | Private Reply | Keep | Replies (1)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 153864
(Total Views: 695)
Posted On: 11/02/2022 6:33:26 AM
Posted By: KenChowder
A basic fact I learned from the arbitration claim helpfully posted on Stockwits: Amarex was the CRO on 20 of the 22 trials CYDY has run. As of Oct. 2021, four of these were ongoing.

This claim was posted over a year ago, meaning the arbitration process must soon come to an end.

One more thing. I've mentioned this here before, but just to reinforce it: Amarex is clearly liable for lost revenues. I held a company involved in a suit that dated from 2006; there were NO revenues when the suit was filed in 2006, and there would be no revenues until 2010, but the judge held that the losing company was liable for revenues that were literally imaginary when the suit was filed. The plaintiff presented a case for revenues that might eventually ensue, and the judge essentially made his own estimate ($100 million in that case). So even though it's not exactly clear now HOW MUCH CYDY would have profited from a successful application for HIV MDR, such things can be estimated, and awarded.

The costs of the toxic financing that resulted from Amarex's mistakes or malfeasance are entirely clear, and they are huge.

To me the only question is whether Sidley Austin can prove that NSF should be on the hook, and for how much. If we can be privy to emails back and forth from NSF and Amarex, it should become clear. And, for NSF, probably pretty expensive.



(19)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us